A prospective study of transsulfuration biomarkers in autistic disorders

David A. Geier, Janet K. Kern, Carolyn R. Garver, James Adams, Tapan Audhya, Mark R. Geier

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

The goal of this study was to evaluate transsulfuration metabolites in participants diagnosed with autism spectrum disorders (ASDs). Transsulfuration metabolites, including: plasma reduced glutathione (GSH), plasma oxidized glutathione (GSSG), plasma cysteine, plasma taurine, plasma sulfate, and plasma free sulfate among participants diagnosed with ASDs (n = 38) in comparison to age-matched neurotypical controls were prospectively evaluated. Testing was conducted using Vitamin Diagnostics, Inc. (CLIA-approved). Participants diagnosed with ASDs had significantly (P < 0.001) decreased plasma reduced GSH, plasma cysteine, plasma taurine, plasma sulfate, and plasma free sulfate relative to controls. By contrast, participants diagnosed with ASDs had significantly (P < 0.001) increased plasma GSSG relative to controls. The present observations are compatible with increased oxidative stress and a decreased detoxification capacity, particularly of mercury, in patients diagnosed with ASDs. Patients diagnosed with ASDs should be routinely tested to evaluate transsulfuration metabolites, and potential treatment protocols should be evaluated to potentially correct the transsulfuration abnormalities observed.

Original languageEnglish (US)
Pages (from-to)386-393
Number of pages8
JournalNeurochemical Research
Volume34
Issue number2
DOIs
StatePublished - Feb 2009

Fingerprint

Biomarkers
Autistic Disorder
Prospective Studies
Plasmas
Sulfates
Glutathione Disulfide
Metabolites
Taurine
Cysteine
Detoxification
Oxidative stress
Clinical Protocols
Mercury
Vitamins
Glutathione
Autism Spectrum Disorder
Oxidative Stress

Keywords

  • Heavy metal
  • Metabolic endophenotype
  • Sulfation
  • Sulfur

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Biochemistry

Cite this

A prospective study of transsulfuration biomarkers in autistic disorders. / Geier, David A.; Kern, Janet K.; Garver, Carolyn R.; Adams, James; Audhya, Tapan; Geier, Mark R.

In: Neurochemical Research, Vol. 34, No. 2, 02.2009, p. 386-393.

Research output: Contribution to journalArticle

Geier, David A. ; Kern, Janet K. ; Garver, Carolyn R. ; Adams, James ; Audhya, Tapan ; Geier, Mark R. / A prospective study of transsulfuration biomarkers in autistic disorders. In: Neurochemical Research. 2009 ; Vol. 34, No. 2. pp. 386-393.
@article{fb8b5c3b671542ba9fab863ea1056129,
title = "A prospective study of transsulfuration biomarkers in autistic disorders",
abstract = "The goal of this study was to evaluate transsulfuration metabolites in participants diagnosed with autism spectrum disorders (ASDs). Transsulfuration metabolites, including: plasma reduced glutathione (GSH), plasma oxidized glutathione (GSSG), plasma cysteine, plasma taurine, plasma sulfate, and plasma free sulfate among participants diagnosed with ASDs (n = 38) in comparison to age-matched neurotypical controls were prospectively evaluated. Testing was conducted using Vitamin Diagnostics, Inc. (CLIA-approved). Participants diagnosed with ASDs had significantly (P < 0.001) decreased plasma reduced GSH, plasma cysteine, plasma taurine, plasma sulfate, and plasma free sulfate relative to controls. By contrast, participants diagnosed with ASDs had significantly (P < 0.001) increased plasma GSSG relative to controls. The present observations are compatible with increased oxidative stress and a decreased detoxification capacity, particularly of mercury, in patients diagnosed with ASDs. Patients diagnosed with ASDs should be routinely tested to evaluate transsulfuration metabolites, and potential treatment protocols should be evaluated to potentially correct the transsulfuration abnormalities observed.",
keywords = "Heavy metal, Metabolic endophenotype, Sulfation, Sulfur",
author = "Geier, {David A.} and Kern, {Janet K.} and Garver, {Carolyn R.} and James Adams and Tapan Audhya and Geier, {Mark R.}",
year = "2009",
month = "2",
doi = "10.1007/s11064-008-9782-x",
language = "English (US)",
volume = "34",
pages = "386--393",
journal = "Neurochemical Research",
issn = "0364-3190",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - A prospective study of transsulfuration biomarkers in autistic disorders

AU - Geier, David A.

AU - Kern, Janet K.

AU - Garver, Carolyn R.

AU - Adams, James

AU - Audhya, Tapan

AU - Geier, Mark R.

PY - 2009/2

Y1 - 2009/2

N2 - The goal of this study was to evaluate transsulfuration metabolites in participants diagnosed with autism spectrum disorders (ASDs). Transsulfuration metabolites, including: plasma reduced glutathione (GSH), plasma oxidized glutathione (GSSG), plasma cysteine, plasma taurine, plasma sulfate, and plasma free sulfate among participants diagnosed with ASDs (n = 38) in comparison to age-matched neurotypical controls were prospectively evaluated. Testing was conducted using Vitamin Diagnostics, Inc. (CLIA-approved). Participants diagnosed with ASDs had significantly (P < 0.001) decreased plasma reduced GSH, plasma cysteine, plasma taurine, plasma sulfate, and plasma free sulfate relative to controls. By contrast, participants diagnosed with ASDs had significantly (P < 0.001) increased plasma GSSG relative to controls. The present observations are compatible with increased oxidative stress and a decreased detoxification capacity, particularly of mercury, in patients diagnosed with ASDs. Patients diagnosed with ASDs should be routinely tested to evaluate transsulfuration metabolites, and potential treatment protocols should be evaluated to potentially correct the transsulfuration abnormalities observed.

AB - The goal of this study was to evaluate transsulfuration metabolites in participants diagnosed with autism spectrum disorders (ASDs). Transsulfuration metabolites, including: plasma reduced glutathione (GSH), plasma oxidized glutathione (GSSG), plasma cysteine, plasma taurine, plasma sulfate, and plasma free sulfate among participants diagnosed with ASDs (n = 38) in comparison to age-matched neurotypical controls were prospectively evaluated. Testing was conducted using Vitamin Diagnostics, Inc. (CLIA-approved). Participants diagnosed with ASDs had significantly (P < 0.001) decreased plasma reduced GSH, plasma cysteine, plasma taurine, plasma sulfate, and plasma free sulfate relative to controls. By contrast, participants diagnosed with ASDs had significantly (P < 0.001) increased plasma GSSG relative to controls. The present observations are compatible with increased oxidative stress and a decreased detoxification capacity, particularly of mercury, in patients diagnosed with ASDs. Patients diagnosed with ASDs should be routinely tested to evaluate transsulfuration metabolites, and potential treatment protocols should be evaluated to potentially correct the transsulfuration abnormalities observed.

KW - Heavy metal

KW - Metabolic endophenotype

KW - Sulfation

KW - Sulfur

UR - http://www.scopus.com/inward/record.url?scp=58849106335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849106335&partnerID=8YFLogxK

U2 - 10.1007/s11064-008-9782-x

DO - 10.1007/s11064-008-9782-x

M3 - Article

VL - 34

SP - 386

EP - 393

JO - Neurochemical Research

JF - Neurochemical Research

SN - 0364-3190

IS - 2

ER -